Chondrosarcoma is the most common primary malignant bone tumor in adults, has no effective systemic treatment, and patients with this disease have poor survival. Altered expression of microRNA (miR) is involved in tumorigenesis, however its role in chondrosarcoma is undetermined. MicroRNA-181a is overexpressed in high grade chondrosarcoma, is upregulated by hypoxia, and increases VEGF expression. Here, the purpose was to determine the mechanism of miR-181a regulation of VEGF, determine if miR-181a overexpression promotes tumor progression, and to evaluate an antagomir-based approach for chondrosarcoma treatment.
Introduction
Chondrosarcoma is the only primary bone cancer without an effective systemic treatment.
Conventional cytotoxic chemotherapy is not effective, and targeted therapeutics have yet to be developed. Chondrosarcoma is highly metastatic and patients typically succumb to pulmonary metastases. The ability to induce sustained angiogenesis is a necessary condition for the two most important traits of cancer: unrestrained growth and development of metastases (1) .
Angiogenesis is usually a tightly regulated process which becomes dysregulated during neoplasia (2) . Angiogenesis and invasion are intimately connected processes and are amplified by hypoxia. In chondrosarcoma, angiogenesis, invasion, and metastasis are a result of CXCR4 signaling, VEGF and MMP1 expression, HIF-1, and potentially microRNA. We have demonstrated that grade II and III chondrosarcomas have more microvascularity and VEGF expression than benign or grade I tumors (3;4) . Vascularity correlates with clinical behavior, since it is primarily grade II and III chondrosarcomas that metastasize (5) . Accordingly, inhibition of tumor angiogenesis could decrease tumor growth and metastasis (6) , and therefore we are interested in pathways regulating these processes.
Hypoxia, which develops as tumors outgrow their blood supply, is an important factor that drives angiogenesis and aggressive behavior in cancer (7) . Hypoxia inducing factor one (HIF-1) is the primary transcription factor that mediates changes in gene expression during hypoxia (8) . We and others have shown that HIF-1 expression is higher in grades II and III chondrosarcoma than in low grade cartilage tumors(3;9;10). We have also shown that in chondrosarcoma cells HIF-1 both directly increases VEGF expression, and indirectly increases VEGF expression by upregulating CXCR4 expression and signaling (11;12) . CXCR4 signaling also increases MMP1 expression, which notably(13;14).
A posttranscriptional mechanism regulating angiogenesis and metastasis in chondrosarcoma could involve microRNA. MicroRNAs are short, endogenous, non-coding RNAs that negatively regulate gene expression by promoting mRNA degradation or by translational repression through complementarity with sequences in the 3' UTR. In cancer, microRNAs can function analogous to tumor suppressors or as oncogenes (oncomiRs) when over-or underexpressed, the net effect dependent on the target genes. MicroRNAs may be master regulators of the malignant phenotype (15) . They have been implicated in angiogenesis (16) and specific microRNAs are upregulated by hypoxia (17) . We have identified miR-181a as a potential oncomiR that is upregulated by hypoxia in chondrosarcoma that also regulates VEGF expression (18) and hypothesize that its overexpression contributes to angiogenesis and metastasis by amplifying CXCR4 signaling.
Materials and methods
Primary Human Chondrosarcoma Tissue. Human chondrosarcoma (HCS) from twenty-three patients and twelve normal articular cartilage specimens were obtained at surgery and either were cultured in complete medium (40% DMEM, 40% MEM, 20% F12) and CS-1 (a gift from Dr. Francis Hornicek, Harvard Medical School, Boston, MA) was cultured in Gibco RPMI 1640 Medium (Life Technologies, Grand Island, NY), all with 10% FBS in a humidified incubator (NuAire Inc, Plymouth, MN) under 5% CO 2 and either normoxia (ambient oxygen) or hypoxia 5 (2% O 2 )(11). JJ was derived from a human grade II chondrosarcoma (19) , CS-1 was derived from human grade III chondrosarcoma and metastasizes in a xenograft mouse model (20) . In studies involving CXCR4 signaling, SDF1 (R&D Systems, Minneapolis, MN) 10-20ng/ml was added to the media. The JJ cell line was authenticated using short tandem repeat (STR) profiling (ATCC, Manassas, VA) and was performed on the source cell line in 1999, 2007, and repeated in 2012. There is 94% similarity between the different time points, the cells are human, and there are no matches with any cell lines in the ATCC data base. The CS-1 cell line was also authenticated using short tandem repeat (STR) profiling (ATCC, Manassas, VA) and was performed in September 2012 and matched the STS profiling performed by the source laboratory in 2011, and there were no matches in the ATCC data base.
RNA Isolation. Total RNA including microRNA was extracted from HCS tissue, cartilage, chondrocytes, JJ and CS-1 cells using miRNeasy Mini Kit (Qiagen, Valencia, CA). The concentration and quality of total RNA were determined with a NanoDrop 2000C spectrophotometer (Thermo Fisher Scientific, Waltham, MA). Samples with purity of 1.8-2 and integrity over 1.6 were used for analysis of miRNA expression.
cDNA synthesis and qPCR. Total RNA was reverse transcribed using the miScript Reverse Transcription kit (Qiagen, Valencia, CA). Quantification of the ubiquitously expressed miRNA, U17a, was used as an internal control which expresses consistently in normoxia and hypoxia. A reaction mixture (20µl) containing the SYBR Green Master Mix (Qiagen), 2ng of cDNA template plus miScript Universal primer and miScript Primer Assay (miR specific primer for miR-181a) in a 96-well plate was used for real-time PCR using miScript SYBR Green PCR kit (Qiagen). The reactions were done in triplicate on the DNA engine Opticon 2 PCR amplification system (Bio-Rad, Hercules, CA). PCR conditions: an initial step at 95 °C for 10 min, followed 6 by 40 cycles of amplification at 94 °C for 10 s, 55 °C for 30s, then 70°C for 30s. To determine the expression level of RGS16, total RNA was analyzed using the Reverse Transcription System (Bio-Rad) followed by real-time PCR with SYBR Green Master Mix (Qiagen). 18S and B2M were used as internal controls (21;22) . The primers for RGS16 and 18s have been previously published (23;24) . The primers for B2M were 5'-GTGGAGCATTCAGACTTGTCTT-3' and 5'-GCGGCATCTTCAAACCTCC-3', respectively. The data analysis was performed as previously described (23;25) . 
immunohistochemistry using CD34 antibody ( Figure 3C ). VEGF in xenograft tumors was also decreased ( Figure 3D ). miR-181a knockdown inhibited cell proliferation in vitro ( Figure 3E) and xenograft tumor volume and weight ( Figure 3F ,G).
MMP activity evaluated with FMT was also decreased in xenograft tumors by miR-181a knockdown (Figure 4 A, B) as was MMP-1 content in xenograft tumors ( Figure 4C ). Most importantly, knockdown of miR-181a decreased lung metastases (Figures 4 D, E) . Anti-miR181a also decreased in vitro invasion in both cell lines (Figure 4 F) .
RGS16 is a target of miR-181a.
To identify potential target genes of miR-181a, we performed a bioinformatics search using three different algorithms, TargetScan (http://www.targetscan.org), miRBase (http://www.mirbase.org), and miRanda (http://www.microrna.org). The latter predicted RGS16 as a target of miR-181a. RGS16 is a negative regulator of CXCR4 activity.
Since we have previously reported increased CXCR4 signaling in chondrosarcoma, we pursued miR-181a and RGS16 as another mechanism that might explain increased CXCR4 signaling in this tumor (12) .
The predicted seeding site for miR-181a is in the RGS16-3'UTR, which is evolutionarily conserved across different species. miR-181a transfection and RGS16 knockdown have similar effectiveness at increasing invasion, and VEGF and MMP-1 expression (Figure 4 G-I) . To confirm the prediction that miR-181a targets RGS16, we created a luciferase reporter construct containing luciferase and the WT or mutated RGS16 3'UTR. The results show that miR-181a transfection inhibits WT RGS16 3'UTR, while knockdown with anti-miR-181a had the opposite effect ( Figure 5A ). There was no effect of miR-181a with the mutated RGS16 3'UTR ( Figure   5B ). We then analyzed the effect of miR-181a transfection and knockdown on RGS16 expression in both cell lines. qRT-PCR showed the expected effects if RGS16 was the target: 
Discussion
In this study we show that in vivo growth in a xenograft chondrosarcoma model increases expression of miR-181a even more than hypoxic cell culture conditions and that expression of miR-181a correlates with tumor grade. We have previously reported that miR-181a increases expression of VEGF in vitro. Here we report that miR-181a also increases MMP1 and at least part of the mechanism by which miR-181a overexpression increases expression of VEGF and MMP1 is by inhibiting RGS16, a negative regulator of CXCR4. miR-181a directly targets have previously reported that HIF-1 directly increases CXCR4 expression in chondrosarcoma, resulting in an indirect mechanism of increased VEGF and MMP1 expression(12;13). Hypoxia regulated transcription of microRNA is yet another mechanism driving the expression of these factors in chondrosarcoma by inhibiting an inhibitor of CXCR4 signaling. miR-181a knockdown restored RGS16 expression and decreased VEGF and MMP1 expression, angiogenesis, and most importantly, lung metastases in a xenograft model ( Figure 6G ).
In cancer, chemokines, their receptors, and innate regulators of receptor activity are important determinants of invasion, angiogenesis, and metastasis. There are four groups of chemokine receptors (26) . Of those, CXCR4 is the one most commonly expressed in tumors, and the one whose expression is most related to development of metastases (27) . The ligand for CXCR4 is the chemokine stromal cell derived factor one (SDF1) (28;29) . CXCR4/SDF1 promotes metastasis by mediating proliferation and migration of tumor cells and enhancing tumor-associated angiogenesis (30) (31) (32) . CXCR4 is a seven-transmembrane G-protein-coupled receptor, whose activation also triggers intracellular signaling cascades, whose downstream targets include MMP1 and VEGF (32;33) . The increased expression of chemokine receptors has been most widely investigated in carcinomas (34) (35) (36) . We and others have found that CXCR4 is overexpressed in chondrosarcoma cells and primary chondrosarcoma(13;37;38). We have also shown that CXCR4 expression is further increased when chondrosarcoma cells are cultured in hypoxia and increased even more so when grown in mice as xenograft tumors (12) . CXCR4 partially inhibits secretion of MMP1 and VEGF(12;13). Intracellular regulation of CXCR signaling involves regulator of G-protein signaling (RGS) proteins, a family of proteins that either enhance or inhibit GPC signaling, the latter by accelerating the deactivation of the activated G alpha subunit through GTPase activity (41) . RGS proteins are critical modulators of signal transduction pathways in normal physiology and in cancer. Individual RGS proteins can either be over-or under-expressed in specific cancers. RGS16 is an inhibitor of CXCR4 signaling in normal megakaryocytes and T lymphocytes (24;42) . In breast cancer, loss of RGS16 enhances growth factor-related PI3K signaling, proliferation, and resistance to tyrosine kinase inhibition (43) . In pancreatic cancer, underexpression of RGS16 is a predictor for lymph node metastasis (44) . Thus, diminished RGS16 leads to cancer progression. Our data is the first to show loss of RGS16 expression in chondrosarcoma and first to show that the mechanism of RGS16 loss involves miR-181a. Another potentially effective method to inhibit CXCR4 signaling, or a method to augment extracellular blockade, would be an intracellular strategy involving anti-miR-181a.
It has been postulated that overexpressed miRs may be master regulators of angiogenesis, invasion, and metastasis through regulation of multiple target genes related to these phenotypes.
Our data show that loss of RGS16 expression results from overexpression of miR-181a. MiR181a is highly conserved across species. Its overexpression is associated with hypoxia(45), progression of myelodysplastic syndromes to acute myeloid leukemia (46) , and has recently been reported in osteosarcoma (47) and breast cancer (48) . Our data as well as a xenograft study using human myeloma cell lines treated with miR-181a antagonists resulted in significant suppression of tumor growth (46) . Thus, miR-181a is a candidate therapeutic target. We have shown that AMD3100 decreases tumor growth, angiogenesis and metastasis in a xenograft model(Sun et al. 
1163-70). The current study shows that miR-181a knockdown has similar effects as AMD3100 (Sun et al. 1163-70) . These data are important in demonstrating that CXCR4 inhibition with either AMD3100 or anti-miR-181a are effective in vivo strategies. Anti-miR181a may inhibit additional pathways than does AMD3100. The advantage of the anti-miR approach is that multiple, partially redundant signaling pathways related to tumor progression may be targeted; one reason anti-miR strategies are under clinical development (49) . Whether antagomir therapy would be more or less durable and effective needs to be evaluated and a method of systemic delivery developed.
There are some limitations to our study. We did not attempt to comprehensively analyze additional mechanisms of miR-181a regulation. Hypoxia and HIF-1 increase miR-181a expression(Sun et al. 907-13), but there may be other mechanisms. We also did not attempt to identify all possible targets of miR-181a. In addition to RGS16, there may be other targets of miR-181a and RGS16 may regulate other pathways besides CXCR4.
In conclusion, miR-181a is an oncomir, whose overexpression results in gain of function by inhibiting an inhibitor of CXCR4 signaling. Antagomir based therapy for chondrosarcoma may prove efficacious and has a potential role in therapeutic strategies. 
